AROAF (Aroa Biosurgery) Other Financing: $-1.03 Mil (TTM As of Mar. 2026)


AROAF Aroa Biosurgery Ltd AROAF
39 GF Score
Price $0.52
GF Value $0.71
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Aroa Biosurgery Other Financing?

Aroa Biosurgery AROAF +35.24% 39 Other Financing is $-1.03 Mil as of Mar. 2026. GuruFocus rates AROAF with a GF Score™ of 39/100 and a GF Value™ of $0.71 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Aroa Biosurgery's Other Financing for the six months ended in Mar. 2026 was $-0.51 Mil.

Aroa Biosurgery's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.03 Mil.

Aroa Biosurgery Other Financing Historical Data

* Premium members only.

The historical data trend for Aroa Biosurgery's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aroa Biosurgery Other Financing Chart

Aroa Biosurgery Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Financing
Get a 7-Day Free Trial -0.66 0.00 0.00 -0.00 -1.06

Aroa Biosurgery Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.37 -0.46 -0.42 -0.52 -0.51
AROAF
39GF Score
Aroa Biosurgery Ltd AROAF
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aroa Biosurgery Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-1.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $-1.03 Mil mean?
Aroa Biosurgery (AROAF) has a Other Financing of $-1.03 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Aroa Biosurgery and its competitors.
Is Aroa Biosurgery's Other Financing too high?
Aroa Biosurgery's current Other Financing is $-1.03 Mil. Overall, Aroa Biosurgery has a GF Score™ of 39/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's Other Financing compare to ABT and SYK?
Aroa Biosurgery's Other Financing of $-1.03 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Medical Devices & Instruments company?
A good Other Financing depends on the Medical Devices & Instruments industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Aroa Biosurgery and its competitors. Aroa Biosurgery's current Other Financing is $-1.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (AROAF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.71, compared to a current price of $0.52 — trading 26.8% below its estimated fair value. The current Other Financing is $-1.03 Mil. Aroa Biosurgery's overall GF Score™ is 39/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Aroa Biosurgery (AROAF), the current Other Financing is $-1.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aroa Biosurgery (AROAF) Overvalued in 2026?

Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued. The current stock price of $0.52 is trading 26.8% below its estimated GF Value™ of $0.71. GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.

Key valuation signals for AROAF:

  • Other Financing: $-1.03 Mil
  • GF Value™: $0.71 vs. price of $0.52 (26.8% below fair value)
  • GF Score™: 39/100 with 1 warning sign

No single metric tells the full story. See the AROAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aroa Biosurgery Business Description

Other Exchanges ARX:Australia
Address 64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
39GF Score

Get the complete analysis for AROAF

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.52
Price
$0.71
GF Value